γδT-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody

Haematologica

Volumn 96, Issue 3, 2011, Pages 400-407

  Braza, Mounia Sabrina ^a   Klein, Bernard ^a,b,c   Fiol, Geneviève ^c   Rossi, Jean François ^b,c  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

T Lymphocytes; Anti CD20 monoclonal antibody; Follicular lymphoma; Ofatumumab; Rituximab

Indexed keywords

CD16 ANTIGEN; GAMMA INTERFERON; GRANZYME; OBINUTUZUMAB; OFATUMUMAB; PERFORIN; RITUXIMAB;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FOLLICULAR LYMPHOMA; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOMA CELL; MALE; PROTEIN SECRETION;

ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; B-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DIPHOSPHATES; FEMALE; FLOW CYTOMETRY; GLYCOPROTEINS; GRANZYMES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PERFORIN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79952343500     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.029520     Document Type: Article

References (58)

1. Carter PJ. Potent antibody therapeutics by design. Nature Rev Immunol. 2006;6(5): 343-57.
2. Grillo-Lopez AJ, White CA, Dallaire BK, Varns CL, Shen CD, Wei A, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol. 2000;1(1):1-9.
3. Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004; 103(12):4416-23.
4. Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045-52.
5. Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 2003;63(17):5480-9.
6. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103(7): 2738-43.
7. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104(6):1793-800.
8. Coiffier B, Tilly H, Pedersen LM, Plesner T, Frederiksen H, van Oers MHJ, et al. HuMax CD20 Fully Human Monoclonal Antibody in chronic lymphocytic leuchemia. Early results from an ongoing phase I/II clinical trial. ASH Annual Meeting Abstracts.2005;106(11):448.
9. Coiffier B. Monoclonal antibodies in the treatment of indolent lymphomas. Best Pract Res Clin Haematol. 2005;18(1):69-80.
10. Bleeker WK, Munk ME, Mackus WJ, van den Brakel JH, Pluyter M, Glennie MJ, et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. B J Haematol.2008;140(3):303-12.
11. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008;111(3):1094-100.
12. Umana P, Moessner E, Bruenker P, Unsin G, Puentener U, Suter T, et al. Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for Enhanced ADCC and Superior Apoptosis Induction. ASH Annual Meeting Abstracts. 2006; 108(11):229-
13. Salles GA, Morschhauser F, Cartron G, Lamy T, Milpied N-J, Thieblemont C, et al. A phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease. ASH Annual Meeting Abstracts. 2008;112(11):234.
14. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol. 2004;336(5): 1239-49.
15. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nature Rev Immunol. 2008;8(1):34-47.
16. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med.2000;6(4):443-6.
17. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti- CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-8.
18. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21(21):3940-7.
19. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733-40.
20. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26(11):1789-96.
21. Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, et al. Anti- CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006;108(8):2648-54.
22. Cittera E, Onofri C, D'Apolito M, Cartron G, Cazzaniga G, Zelante L, et al. Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. Cancer Immunol Immunother. 2005;54(3): 273-86.
23. Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood. 2009;113(16):3809-12.
24. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004; 104(9):2635-42.
25. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nature Rev Immunol.2007;7(5): 329-39.
26. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294(1-2):15-22.
27. Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods. 2005; 304(1-2):88-99.
28. Espinosa E, Belmant C, Pont F, Luciani B, Poupot R, Romagne F, et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J Biol Chem.2001;276(21):18337-44.
29. Viey E, Laplace C, Escudier B. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 2005;5(6):973-86.
30. Burjanadze M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C, et al. In vitro expansion of gamma delta T cells with antimyeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol. 2007;139 (2):206-16.
31. Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, et al. Phosphostimactivated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol. 2005;174(3):1338-47.
32. Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E, et al. V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol. 2005;175 (8):5481-8.
33. Bonneville M, Fournie JJ. Sensing cell stress and transformation through Vgamma9Vdelta2 T cell-mediated recognition of the isoprenoid pathway metabolites. Microbes Infect. 2005;7(3):503-9.
34. Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 2007;67(1):5-8.
35. Casetti R, Perretta G, Taglioni A, Mattei M, Colizzi V, Dieli F, et al. Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2. J Immunol. 2005;175(3):1593-8.
36. Sicard H, Ingoure S, Luciani B, Serraz C, Fournie JJ, Bonneville M, et al. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol. 2005;175(8):5471-80.
37. Kobayashi H, Tanaka Y, Yagi J, Toma H, Uchiyama T. Gamma/delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunol Immunother. 2001; 50(3):115-24.
38. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102(1):200-6.
39. Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood. 2003;102 (6):2310-1.
40. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67(15):7450-7.
41. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2008;57(11):1599-609.
42. Braza MS, Caraux A, Rousset T, Lafaye de Micheaux S, Sicard H, Squiban P, et al. gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes. J Immunol. 2010;184(1):134-40.
43. Lafont V, Liautard J, Liautard JP, Favero J. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen. J Immunol. 2001;166(12): 7190-9.
44. Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C, et al. Differentiation of effector/ memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med. 2003;198(3):391-7.
45. Angelini DF, Borsellino G, Poupot M, Diamantini A, Poupot R, Bernardi G, et al. FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood. 2004;104(6):1801-7.
46. Poupot M, Pont F, Fournie JJ. Profiling blood lymphocyte interactions with cancer cells uncovers the innate reactivity of human gamma delta T cells to anaplastic large cell lymphoma. J Immunol. 2005;174(3):1717-22.
47. Tokuyama H, Hagi T, Mattarollo SR, Morley J, Wang Q, Fai-So H, et al. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab. Int J Cancer.2008;122 (11):2526-34.
48. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood.1997;90(8):2863-92.
49. Gertner J, Wiedemann A, Poupot M, Fournie JJ. Human gammadelta T lymphocytes strip and kill tumor cells simultaneously. Immunol Lett. 2007;110(1):42-53.
50. Gertner-Dardenne J, Poupot M, Gray B, Fournie JJ. Lipophilic fluorochrome trackers of membrane transfers between immune cells. Immunol Invest. 2007;36(5-6):665-85.
51. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol.2007;44(16):3823-37.
52. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278(5): 3466-73.
53. Wright A, Morrison SL. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol.1997;15(1):26-32.
54. Gertner-Dardenne J, Bonnafous C, Bezombes C, Capietto AH, Scaglione V, Ingoure S, et al. Bromohydrin pyrophosphate enhances antibody-dependent cellmediated cytotoxicity induced by therapeutic antibodies. Blood. 2009;113(20): 4875-84.
55. Viey E, Lucas C, Romagne F, Escudier B, Chouaib S, Caignard A. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients. J Immunother. 2008;31 (3):313-23.
56. Choudhary A, Davodeau F, Moreau A, Peyrat MA, Bonneville M, Jotereau F. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. J Immunol. 1995;154(8):3932-40.
57. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science.2005;309(5732):264-8.
58. Moser B, Brandes M. Gammadelta T cells: an alternative type of professional APC. Trends Immunol. 2006;27(3):112-8.